Clinical Trial Update: Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy (Tablets) With Recombinant Bet v1 [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, and pharmacodynamic effects of a sublingual immunotherapy tablet containing recombinant Bet v1 for birch pollen–r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis Seasonal
• Allergic Rhinoconjunctivitis

Drugs mentioned

• Sublingual immunotherapy tablet containing recombinant Bet v1 (recombinant Bet v1 allergen)

Snippet

Sponsor: Stallergenes Greer | Conditions: Birch Pollen-Related Rhinoconjunctivitis, Rhinitis, Allergic, Seasonal | Phase 1 | Status: COMPLETED